Trial · NCT04847518
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of symptoms of mild COVID-19: number of days before symptoms disappear | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Time (days) from randomization to symptoms disappear |
| Primary | The severity of the COVID-19 total and individual symptoms: headache, loss of smell, gustatory dysfunction, rhinorrhoea, nasal congestions, cough, sore throat, asthenia, myalgia, and fever | Change from baseline during the period of the treatment and follow up (trough 21 days after randomization) | Time (days) from randomization to the relief of total and individual mild COVID symptoms scores. |
| Primary | Duration of infection | from Day 1 to Day 14 after randomisation | Time (days) from randomization to negative SARS-Cov-2 PCR test |
| Primary | Number of participants clinically recovered | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Number of participants (n) without symptoms of mild COVID |
| Secondary | Severity of Respiratory symptoms and quality of life scores | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Wisconsin Upper Respiratory Symptom Survey Questionary Score |
| Secondary | Cognitive performance test | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | d2-test of attention score |
| Secondary | Immune response marker | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | IL-6 concentration in the serum, pg/ml. |
| Secondary | Hypercoagulation marker | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization | Dimer-D, ng/ml |
| Secondary | Inflammatory marker | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | C-reactive protein, mg/L |
| Secondary | Physical activity | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | Assessed by Habitual Physical Activity Questionnaire Score |
| Other | Paracetamol intake | Change from baseline during the period of the treatment and follow up (from Day 1 to Day 14 and day 21 after randomization) | The number (n) of daily doses (4g) of paracetamol consumed during 14 days from randomization. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04847518/registered